U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

217415US0PCT

FORM PTO-1390 (Modified) (REV 11-2000)

U.S. DEPARTMENT

COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371

1 10

INTERNATIONAL APPLICATION NO.
PCT/FR00/01857

INTERNATIONAL FILING DATE 30 JUNE 2000

PRIORITY DATE CLAIMED

| | <u> </u> | 2C1/FR00/01857 30 JUNE 2000 01 JULY 1999 | | | | | | | | |
|--------------------|----------|---|--|--|--|--|--|--|--|--|
| | N C | OVENTION CITRULLINE DERIVATIVES AND THEIR USE FOR DIAGNOSING OR TREATING RHEUMATOID FIS | | | | | | | | |
| APPLIC | ANT | T(S) FOR DO/EO/US | | | | | | | | |
| | | RE, et al. | | | | | | | | |
| Applica | int h | erewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: | | | | | | | | |
| 1. | × | This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. | | | | | | | | |
| 2. [| | This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. | | | | | | | | |
| 3. (| X | This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include itens (5), (6), (9) and (24) indicated below. | | | | | | | | |
| 4. | X | The US has been elected by the expiration of 19 months from the priority date (Article 31). | | | | | | | | |
| 5. [| XI | A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) | | | | | | | | |
| ì | | a. is attached hereto (required only if not communicated by the International Bureau). | | | | | | | | |
| | | b. As been communicated by the International Bureau. | | | | | | | | |
| | | c. is not required, as the application was filed in the United States Receiving Office (RO/US). | | | | | | | | |
| j 6. [| × | An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). | | | | | | | | |
| - - - | | a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). | | | | | | | | |
| ∦ ∮7. [| XI | Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) | | | | | | | | |
| <i>∓</i> /. t | △ | a. are attached hereto (required only if not communicated by the International Bureau). | | | | | | | | |
| 1 | | b. have been communicated by the International Bureau. | | | | | | | | |
| | | c. have not been made; however, the time limit for making such amendments has NOT expired. | | | | | | | | |
| | | d. \(\simeq \) have not been made and will not be made. | | | | | | | | |
| ∄1 ∳8. [| | An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). | | | | | | | | |
| ≤ . | | An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). | | | | | | | | |
| | | An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). | | | | | | | | |
| 11. [| | A copy of the International Preliminary Examination Report (PCT/IPEA/409). | | | | | | | | |
| 12. | X | A copy of the International Search Report (PCT/ISA/210). | | | | | | | | |
| Iten | ns 13 | 3 to 20 below concern document(s) or information included: | | | | | | | | |
| 13. | X | An Information Disclosure Statement under 37 CFR 1.97 and 1.98. | | | | | | | | |
| 14. (| | An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. | | | | | | | | |
| 15. | X | A FIRST preliminary amendment. | | | | | | | | |
| 16. | | A SECOND or SUBSEQUENT preliminary amendment. | | | | | | | | |
| 17. [| | A substitute specification. | | | | | | | | |
| 18. [| | A change of power of attorney and/or address letter. | | | | | | | | |
| | _ | A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. | | | | | | | | |
| _ | _ | A second copy of the published international application under 35 U.S.C. 154(d)(4). | | | | | | | | |
| | _ | A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). | | | | | | | | |
|) / (<u>-</u> | | Certificate of Mailing by Express Mail | | | | | | | | |
| 23. | | Other items or information: | | | | | | | | |
| | | Notice of Priority PTO-1449 | | | | | | | | |
| | | Drawings (3 sheets) | | | | | | | | |
| | | | | | | | | | | |

| U.S. APPLICATION | 0/019439 | PCT/FR00 | | | | | SUSOPCT | | |
|---|--|---|---------------------|-------------------|--------|---------------------------|---------------------------------------|--|--|
| 24. The fo | llowing fees are submitted:. | | | | | CALCULATIONS | S PTO USE ONLY | | |
| ☐ Neither inte | AL FEE (37 CFR 1.492 (a) (1) - ernational preliminary examination al search fee (37 CFR 1.445(a)(2)) tional Search Report not prepared | fee (37 CFR 1.482) nor paid to USPTO | | . \$104 | 0.00 | | | | |
| | al preliminary examination fee (37 International Search Report prepare | CFR 1.482) not paid to ared by the EPO or JPO. | | . \$89 | 0.00 | | | | |
| ☐ International but internat | al preliminary examination fee (37 ional search fee (37 CFR 1.445(a) | CFR 1.482) not paid to U(2)) paid to USPTO | JSPTO | \$74 | 0.00 | | | | |
| ☐ International but all claim | al preliminary examination fee (37 ns did not satisfy provisions of PC | CFR 1.482) paid to USP' T Article 33(1)-(4) | TO | . \$71 | 0.00 | | | | |
| ☐ Internationa and all clair | al preliminary examination fee (37 ns satisfied provisions of PCT Art ENTER APPROPRI | icle 33(1)-(4) | | | 0.00 | | | | |
| Surcharge of \$130. | 00 for furnishing the oath or decla | | □ 20 | |) | \$890.00 | | | |
| months from the ea | nrliest claimed priority date (37 C. | FR 1.492 (e)). NUMBER EXTRA | Ţ | RATE | | \$130.00 | | | |
| Total claims | 10 - 20 = | 0 | | x \$18.0 | | \$0.00 | | | |
| Independent claims | | 0 | | x \$84.0 | 0 | \$0.00 | | | |
| | t Claims (check if applicable). | | | | | \$0.00 | | | |
| | | ABOVE CALCU | | | = | \$1,020.00 | | | |
| ☐ Applicant clair reduced by 1/ | ims small entity status. See 37 CF 2. | | | | | \$0.00 | | | |
| | | **** | SUBT | OTAL | = | \$1,020.00 | | | |
| Processing fee of \$ months from the ea | 130.00 for furnishing the English rliest claimed priority date (37 Cl | translation later than FR 1.492 (f)). | □ 20 | □ 30 |) + | \$0.00 | | | |
| | | TOTAL NATIO | NAL | FEE | = | \$1,020.00 | | | |
| Fee for recording the accompanied by an | he enclosed assignment (37 CFR 1 appropriate cover sheet (37 CFR | .21(h)). The assignment 3.28, 3.31) (check if app | mușt be olicable | e). | | \$0.00 | | | |
| f t | | TOTAL FEES EI | NCL | OSED | = | \$1,020.00 | | | |
| | · | | | - | | Amount to be: refunded | \$ | | |
| | | | | | | charged | 2 | | |
| b. 🔲 Plea | | | | | | | | | |
| c. 🗵 The | uplicate copy of this sheet is enclored commissioner is hereby authorized. | ed to charge any addition | al fees | which may | be rec | quired, or credit any | overpayment | | |
| | Deposit Account No. 15-0030 | <u> </u> | | | | | _ | | |
| | s are to be charged to a credit card ormation should not be included | | | | - | - | | | |
| | appropriate time limit under 3' ust be filed and granted to resto | | | | | | | | |
| SEND ALL CORR | ESPONDENCE TO: | | | | // | wels fach | 1 -01 | | |
| | | | | SIGNATI | | was you | | | |
| 5 | 140000000000000000000000000000000000000 | | | Norman | ΕO | blon | | | |
| | | NAME | | | | | | | |
| | | 1 | | | | | | | |
| | 22850 | | | 24,618 | | | | | |
| | 22850 | | | 24,618 REGISTE | RATIO | ON NUMBER | | | |
| | | 20hor | | | | | | | |
| (703) 413-3000 | 22850 Surinder S Registration No | | | | De | | · · · · · · · · · · · · · · · · · · · | | |

JC13 Rec'd PCT/PTO 3 1 DEC 2001

Docket No.

217415US0PCT

IN RE APPLICATION OF:

Guy SERRE, et al.

SERIAL NO:

NEW U.S. PCT APPLICATION BASED ON PCT/FR00/01857

FILED:

HEREWITH

FIBRIN CITRULLINE DERIVATIVES AND THEIR USE FOR DIAGNOSING OR TREATING

FOR:

RHEUMATOID ARTHRITIS

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Transmitted herewith is an amendment in the above-identified application.

No additional fee is required

☐ Small entity status of this application under 37 C.F.R. §1.9 and §1.27 is claimed.

Additional documents filed herewith:

English Translation of Specification/Notice of Priority/PCT Transmittal Letter International Search Report/Drawings (3 sheets)/Preliminary Amendment Information Disclosure Statement/PTO-1449/Check for \$1,020.00

The Fee has been calculated as shown below:

| CLAIMS | CLAIMS REMAINING | | HIGHEST NUMBER PREVIOUSLY PAID | NO. EXTRA CLAIMS | | RATE | | CALCULATIONS |
|---|---------------------|--------|---|------------------------|----|--------|--------|--------------|
| TOTAL | 10 | MINUS | 20 | 0 | × | \$18 | = | \$0.00 |
| INDEPENDENT | 1 | MINUS | 3 | 0 | × | \$84 | = | \$0.00 |
| | | ☐ MULT | MULTIPLE DEPENDENT CLAIMS | | | | = | \$0.00 |
| TOTAL OF ABOVE CALCULATION | | | | | NS | \$0.00 | | |
| Reduction by 50% for filing by Small Entity Recordation of Assignment + \$40 TOTAL | | | | | | | \$0.00 | |
| | | | | | | = | \$0.00 | |
| | | | | | | TOT | ٩L | \$0.00 |

☐ A check in the amount of \$0.00 is attached.

- Please charge any additional Fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.
- ☑ If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136, and any additional fees required under 37 C.F.R. §1.136 for any necessary extension of time may be charged to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Surinder Sachar

Registration No. 34,423

22850

Customer Number 22850 Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 10/01) **DOCKET NO.: 217415 US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Guy SERRE, et al. SERIAL NO.: NEW U.S. PCT APPLICATION

FILED: HEREWITH

INTERNATIONAL APPLICATION NO.: PCT/FR00/01857

INTERNATIONAL FILING DATE: June 30, 2000

FOR: FIBRIN CITRULLINE DERIVATIVES AND THEIR USE FOR DIAGNOSING OR

TREATING RHEUMATOID ARTHRITIS

REQUEST FOR PRIORITY UNDER 35 U.S.C. 119 AND THE INTERNATIONAL CONVENTION

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In the matter of the above-identified application for patent, notice is hereby given that the applicant claims as priority:

COUNTRY

APPLICATION NO

DAY/MONTH/YEAR

01 July 1999

France

99 08470

Certified copies of the corresponding Convention application(s) were submitted to the International Bureau in PCT Application No. PCT/FR00/01857.

> Respectfully submitted, OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

(703) 413-3000 Fax No. (703) 413-2220 (OSMMN 1/97)

Norman F. Oblon Attorney of Record Registration No. 24,618

Surinder Sachar

Registration No. 34,423